Listar INIBIC-OCT - Artigos por título
Mostrando ítems 11-21 de 21
-
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
(Taylor & Francis, 2017-08-28)[Abstract] Background: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. Objective: To evaluate ... -
Fructose transporter Glut5 expression in clear renal cell carcinoma
(Spandidos, 2010-12-10)[Abstract] Renal cell carcinomas (RCC) can be subclassified for general purposes into clear cell, papillary cell, chromophobe cell carcinomas and oncocytomas. Other tumours such as collecting duct, medullary, mucinous ... -
Hakai reduces cell-substratum adhesion and increases epithelial cell invasion
(BioMed Central, 2011-11-03)[Abstract] Background. The dynamic regulation of cell-cell adhesions is crucial for developmental processes, including tissue formation, differentiation and motility. Adherens junctions are important components of the ... -
miR-203 regulates cell proliferation through Its influence on Hakai expression
(PLoS, 2012-12-20)Gene expression is potently regulated through the action of microRNAs (miRNAs). Here, we present evidence of a miRNA regulating Hakai protein. Hakai was discovered as an E3 ubiquitin-ligase that mediates the posttranslational ... -
Multiple biomarker tissue arrays: a computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway
(BioMed Central, 2012-09-01)[Abstract] Background. Many studies have demonstrated genetic and environmental factors that lead to renal cell carcinoma (RCC) and that occur during a protracted period of tumourigenesis. It appears suitable to identify ... -
New insights into molecular mechanisms of sunitinib-associated side effects
(American Association for Cancer Research, 2011-12)[Abstract] The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. ... -
Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition
(Springer, 2013-05-29)[Abstract] Epithelial-to-mesenchymal transition (EMT), one of the crucial steps for carcinoma cells to acquire invasive capacity, results from the disruption of cell–cell contacts and the acquisition of a motile mesenchymal ... -
Potential role of sugar transporters in cancer and their relationship with anticancer therapy
(Hindawi, 2010-06-20)[Abstract] Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number of transporter proteins to introduce sugars through their plasma membrane. ... -
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer
(Taylor & Francis, 2015-01-02)[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to ... -
Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells
(BioMed Central, 2014-07-10)[Abstract] Background. Vinflunine (VFL) is a microtubule-targeting drug that suppresses microtubule dynamics, showing anti-metastatic properties both in vitro and in living cancer cells. An increasing body of evidence ... -
Sunitinib-induced asthenia: from molecular basis to clinical relief
(Taylor & Francis, 2011-11-01)[Abstract] Asthenia-fatigue syndrome (AFS) is defined as a persistent, subjective sense of tiredness related to cancer or its treatment and greatly impacts quality of life among cancer patients. All tyrosine kinase inhibitors, ...
